The clinical sample and the xenograft tumours present some of the chromosome alterations that have already been frequently described in the genomic profiles of BRCA2-mutated tumours, as gains of 8q and 20q, and loss of 13q (Palacios et al, 2008). Here, BRCA2 is linked to neoplasm.